Wall Street Has a Positive Outlook on uniQure N.V. (QURE) Despite Challenges From The FDA

​uniQure N.V. (NASDAQ:QURE) is one of the Hottest Small Cap Stocks to Buy Now. Wall Street has a positive outlook on uniQure N.V. (NASDAQ:QURE) despite the regulatory challenges from the FDA for its experimental gene therapy called AMT-130. On November 12, Yanan Zhu from Wells Fargo also reiterated a Buy rating on uniQure N.V. (NASDAQ:QURE), but lowered the price target from $80 to $60. A day earlier, TD Cowen analyst Joseph Thome had maintained a Buy rating on the stock without disclosing any price target.

​Earlier in September, uniQure N.V. (NASDAQ:QURE) presented critical results from a three-year study of their experimental gene therapy called AMT-130, aimed at treating Huntington’s disease. The results showed a significant reduction in disease progression.

​However, regardless of the encouraging results, the FDA on November 3 provided negative feedback for AMT-130. As per the management, the FDA no longer thinks the data from their early Phase I/II studies of AMT-130 is enough to support their main evidence for getting approval to sell the therapy. As a result, the timing for the pre-Biologics License Application for AMT-130 is now unclear.

​Analyst Joseph Thome from TD Cowen noted that management’s confidence in the data and potential of AMT-130 remains robust. He mentioned the company is in active engagement with the FDA to explore a viable way forward. Thome remains confident in the company’s ability to address these concerns effectively.

uniQure N.V. (NASDAQ:QURE) is a biotechnology company based in the Netherlands that develops gene therapies designed to be given once and potentially cure severe genetic diseases.

While we acknowledge the potential of QURE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.